ASRS 2023: Annexon to share results of ARCHER Phase 2 trial for the treatment of geographic atrophy

Annexon, Inc. will present results from the ongoing ARCHER Phase 2 trial in patients with GA at ASRS. Image credit: ©Seventyfour – stock.adobe.com

Annexon, Inc. will present results from the ongoing ARCHER Phase 2 trial in patients with geographic atrophy (GA) at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting. This meeting will take place July 28 – August 1, 2023 in Seattle, Washington.

The company’s presentation details are as follows:

• Date and Time: Sunday, July 30, 2023 at 9:00 am PT
• Title: Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration with Intravitreal ANX007: Results of the ARCHER Study
• Presenter: Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER
• Session: Dry AMD Symposium 2

In addition to this presentation, the Annexon management will host a conference call, joined by Heier, on Monday, July 31, 2023 at 1:30 pm PT. The webcast and accompanying slides will be available under the Events & Presentations section on the Investors & Media page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days.

Reference:

1. Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023. Annexon Inc. July 24, 2023. Accessed July 25, 2023. https://www.biospace.com/article/releases/annexon-to-report-archer-phase-2-trial-results-in-geographic-atrophy-at-asrs-2023/